These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3893732)

  • 1. Effects on migraine headache of MDL 72,222, an antagonist at neuronal 5-HT receptors. Double-blind, placebo-controlled study.
    Loisy C; Beorchia S; Centonze V; Fozard JR; Schechter PJ; Tell GP
    Cephalalgia; 1985 Jun; 5(2):79-82. PubMed ID: 3893732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors.
    Orwin JM; Fozard JR
    Eur J Clin Pharmacol; 1986; 30(2):209-12. PubMed ID: 3709648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 5-HT(3) receptor antagonists on daily alcohol intake under acquisition, maintenance, and relapse conditions in alcohol-preferring (P) rats.
    Rodd-Henricks ZA; McKinzie DL; Edmundson VE; Dagon CL; Murphy JM; McBride WJ; Lumeng L; Li TK
    Alcohol; 2000 May; 21(1):73-85. PubMed ID: 10946160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors.
    Fozard JR
    Naunyn Schmiedebergs Arch Pharmacol; 1984 May; 326(1):36-44. PubMed ID: 6472484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.
    Chappell AS; Bay JM; Botzum GD; Cohen ML
    Neuropharmacology; 1994; 33(3-4):509-13. PubMed ID: 7984290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The depolarizing action of 5-hydroxytryptamine on rabbit vagal primary afferent and sympathetic neurones and its selective blockade by MDL 72222.
    Azami J; Fozard JR; Round AA; Wallis DI
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Feb; 328(4):423-9. PubMed ID: 3990828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
    Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
    Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study.
    Honkaniemi J; Liimatainen S; Rainesalo S; Sulavuori S
    Headache; 2006 May; 46(5):781-7. PubMed ID: 16643581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind comparison of granisetron and placebo for the treatment of acute migraine in the emergency department.
    Rowat BM; Merrill CF; Davis A; South V
    Cephalalgia; 1991 Nov; 11(5):207-13. PubMed ID: 1663423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
    Diener HC
    Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
    Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
    Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sumatriptan suppositories for the acute treatment of migraine. S2B351 Study Group.
    Tepper SJ; Cochran A; Hobbs S; Woessner M
    Int J Clin Pract; 1998; 52(1):31-5. PubMed ID: 9536565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
    Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
    Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The way to serotonergic use and abuse in migraine.
    Nicolodi M; Del Bianco PL; Sicuteri F
    Int J Clin Pharmacol Res; 1997; 17(2-3):79-84. PubMed ID: 9403359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.
    Sang CN; Ramadan NM; Wallihan RG; Chappell AS; Freitag FG; Smith TR; Silberstein SD; Johnson KW; Phebus LA; Bleakman D; Ornstein PL; Arnold B; Tepper SJ; Vandenhende F
    Cephalalgia; 2004 Jul; 24(7):596-602. PubMed ID: 15196302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propranolol and femoxetine, a HT-uptake inhibitor, in migraine prophylaxis. A double-blind crossover study.
    Andersson PG; Petersen EN
    Acta Neurol Scand; 1981 Oct; 64(4):280-8. PubMed ID: 7032183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.